Physicochemical Properties
| Molecular Formula | C41H50O11S3 |
| Molecular Weight | 815.02 |
| CAS # | 2408050-83-7 |
| Appearance | Typically exists as solid at room temperature |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | Inducer of apoptosis chemical 12b (apoptosis inducer 4) (0-50 µM, 72 hours) inhibits the growth of cancer cells but does not appear to be harmful to normal cells [1]. In K562 cells, apoptosis inducer 4 (0–2 µM, 48 hours) induces cell cycle arrest in the S phase, and in HepG2 cells, in the G1 phase [1]. In K562 cells, apoptosis inducer 4 (0–4 µM, 24 and 48 hours) causes pyknosis and lowers mitochondrial membrane potential [1]. K562 and HepG2 cells undergo apoptosis when exposed to Apoptosis Inducer 4 (0–2 µM) for 72 hours [1]. |
| Cell Assay |
Cell Proliferation Assay[1] Cell Types: HepG2, MCF-7, HCT-116, B16, K562, L-02 and PBMC Tested Concentrations: 0-50 µM Incubation Duration: 72 hrs (hours) Experimental Results: Demonstrated anti-proliferative activity with IC50 value of 2.57 ± 0.12, 16.15 ± 1.02, 5.81 ± 1.17, 12.94 ± 0.88, 0.95 ± 0.06, 17.59 ± 0.93 and >50 µM for HepG2, MCF-7, HCT-116, B16, K562, L-02 and PBMC cells respectively . Cell cycle analysis [1] Cell Types: K562 and HepG2 Cell Tested Concentrations: K562 and HepG2 cells Incubation Duration: 48 h Experimental Results: The K562 cell cycle was arrested in the S phase, and the HepG2 cell cycle was arrested in the G1 phase. Cell apoptosis analysis [1] Cell Types: K562 and HepG2 cells Tested Concentrations: K562 and HepG2 cells Incubation Duration: 72 h Experimental Results: The apoptosis rate of K562 and HepG2 cells increased Dramatically in a concentration-dependent manner. |
| References |
[1]. Hydrogen sulfide releasing oridonin derivatives induce apoptosis through extrinsic and intrinsic pathways. Eur J Med Chem. 2020 Feb 1;187:111978. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2270 mL | 6.1348 mL | 12.2696 mL | |
| 5 mM | 0.2454 mL | 1.2270 mL | 2.4539 mL | |
| 10 mM | 0.1227 mL | 0.6135 mL | 1.2270 mL |